BRCA2 and ovarian carcinoma: Furthermore, a recent study by Datta et al. showed that WRN inhibitor can potentiate the cytotoxicity of olaparib in BRCA2-mutated ovarian cancer cells that otherwise normally exhibit de novo or acquired PARPi resistance [95].